Bioleaders Corporation Cash Flow-to-Debt Ratio
Bioleaders Corporation cash flow-to-debt ratio. Bioleaders Corporation (142760) has a Cash Flow-to-Debt Ratio of -0.11x as of June 2026, meaning its operating cash flow of ₩-932.70 Million could theoretically repay 0% of its total liabilities (₩8.29 Billion) in one year. Check Bioleaders Corporation earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Bioleaders Corporation (2015–2025)
Cash flow-to-debt ratio of Bioleaders Corporation from 2015 to 2025. Historical debt coverage capacity for Bioleaders Corporation across 11 annual periods. Check cash flow reinvestment rate of Bioleaders Corporation to assess the company's total reinvestment commitment from operating cash flow.
Bioleaders Corporation Cash Flow-to-Debt Ratio by Year (2015–2025)
Bioleaders Corporation cash flow-to-debt ratio by year from 2015 to 2025. Year-by-year debt coverage analysis for Bioleaders Corporation. For the full cash flow conversion analysis, see Bioleaders Corporation (142760) cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.50x | ₩-5.97 Billion | ₩12.04 Billion | ▼ -2364.8% |
| 2024 | -0.02x | ₩-501.75 Million | ₩24.94 Billion | ▼ -104.3% |
| 2023 | 0.47x | ₩6.18 Billion | ₩13.28 Billion | ▲ +386.1% |
| 2022 | -0.16x | ₩-20.60 Billion | ₩126.73 Billion | ▼ -364.0% |
| 2021 | -0.04x | ₩-5.04 Billion | ₩143.74 Billion | ▼ -3.4% |
| 2020 | -0.03x | ₩-5.43 Billion | ₩160.09 Billion | ▼ -91.9% |
| 2019 | -0.02x | ₩-2.20 Billion | ₩124.30 Billion | ▲ +73.9% |
| 2018 | -0.07x | ₩-8.77 Billion | ₩129.79 Billion | ▲ +98.1% |
| 2017 | -3.54x | ₩-8.53 Billion | ₩2.41 Billion | ▼ -90.7% |
| 2016 | -1.85x | ₩-7.70 Billion | ₩4.15 Billion | ▼ -53.1% |
| 2015 | -1.21x | ₩-4.83 Billion | ₩3.99 Billion | — |